By Dr Emmanuel Eni Amadi, PhD, MBA
Medical Scientist | Adult ADHD Clinician | GPhC Registered Pharmacist Independent Prescriber | UKAAN-Trained
Date of publication: 06 November 2026 | ADHD Clinical Evidence Series
A landmark study of 148,581 people links ADHD medication to lower rates of suicidal behaviour, substance misuse, road accidents and criminality. The findings challenge us to think differently about diagnosis, treatment and the true cost of leaving people without appropriate support.
1. The Human Story Behind the Statistics
Imagine a young adult who has spent years being told to concentrate harder.
At school, they were described as careless. At university, they struggled with deadlines. At work, their performance appeared inconsistent despite their intelligence and determination.
They eventually seek help, only to discover that the difficulties affecting their education, relationships, confidence and everyday functioning may be associated with previously unrecognised ADHD.
Now imagine that appropriate assessment and treatment might improve more than concentration.
It might also be associated with safer driving, reduced substance-related harm and better mental-health outcomes.
This is why a major study published in The BMJ in August 2025 deserves renewed attention.
Reported by BBC health correspondent Philippa Roxby on 14 August 2025, the study investigated whether ADHD medication was associated with outcomes extending well beyond the core symptoms of inattention, hyperactivity and impulsivity [1].
The findings were striking.
But their significance lies not simply in the percentages. It lies in the possibility that effective ADHD care may influence important aspects of everyday life.
A diagnosis should never become the end of a clinical journey. For many people, it is the beginning of understanding what appropriate support might achieve.
2. What Did the Swedish Study Discover?
Researchers from Karolinska Institutet and collaborating international institutions analysed Swedish national healthcare and administrative registers covering 2007–2020.
The study included 148,581 people aged 6–64 years who had received a new ADHD diagnosis.
Of these, 84,282 people, approximately 57%, started ADHD medication within three months of diagnosis. Methylphenidate was the most commonly prescribed initial treatment.
Using a methodology known as target trial emulation, researchers compared outcomes associated with starting medication against outcomes associated with not starting medication, with follow-up extending over two years [2].
The results were clinically important.
Relative reductions associated with medication initiation
Figure 1: Figure 1. Associations between ADHD medication initiation and selected adverse outcomes in a Swedish population-based study of 148,581 individuals. Suicidal-behaviour first-event rates were estimated at 14.5 versus 16.9 events per 1,000 person-years for medication initiation and non-initiation, respectively. The 17% relative reduction represents an observational association, not proof of causation. Data adapted from Zhang et al. (2025), The BMJ. DOI: 10.1136/bmj-2024-083658.
Outcomes:
Lower rate of first occurrence:
Suicidal behaviour - 17%.
Substance misuse - 15%.
Transport accidents - 12%.
Criminality - 13%.
2. Recurent Events:
For recurrent events, medication was associated with lower rates of suicidal behaviour (15%), substance misuse (25%), accidental injuries (4%), transport accidents (16%) and criminality (25%) [2].
These figures represent relative associations, not absolute reductions in an individual's probability of experiencing these outcomes.
For example, the study estimated first suicidal-behaviour event rates of 14.5 versus 16.9 per 1,000 person-years in the medication-initiation and non-initiation groups, respectively.
Importantly, the reduction in first-time accidental injuries was not statistically significant.
Although researchers used sophisticated methods to account for measured differences between groups, the study was observational. It cannot establish that medication alone caused the observed improvements.
Nevertheless, it provides substantial real-world evidence supporting further investigation of ADHD treatment's wider benefits.
3. ADHD Is More Than a Problem with Attention
Consider an adult who repeatedly forgets appointments, struggles to organise household finances, misses important deadlines and experiences persistent emotional frustration.
Their challenges may be interpreted as laziness, irresponsibility or a lack of commitment.
But ADHD can affect executive functioning in the pre-frontal cortex of the brain: the cognitive processes involved in planning, prioritising, inhibiting responses, organising information and regulating behaviour.
The World Federation of ADHD International Consensus Statement, endorsed by an international group of researchers, identified 208 evidence-based conclusions about ADHD and its clinical consequences [3].
The disorder is associated with difficulties extending across education, employment, relationships, mental health and daily functioning.
However, these associations should never be used to stereotype individuals with ADHD.
Most people with ADHD do not engage in criminal behaviour, and having ADHD does not mean someone will develop substance misuse problems or experience suicidal behaviour.
The relevant message is that certain risks may be elevated at the population level and that appropriate care may help reduce some of those risks.
Behind every statistic is an individual whose circumstances, strengths and clinical needs deserve careful consideration.
4. Evidence Beyond Sweden: What International Research Tells Us
The Swedish findings are not isolated.
In the United States, a study published in JAMA Psychiatry examined more than 2.3 million people with ADHD using national insurance claims data.
Researchers found that periods in which individuals received ADHD medication were associated with lower rates of motor vehicle crashes.
Within-person comparisons suggested a 38% lower crash risk among men and a 42% lower risk among women during medicated months compared with unmedicated months [4].
These findings are especially relevant to the everyday responsibilities of adulthood: commuting, transporting children, travelling for work and operating vehicles safely.
A separate Swedish study published in JAMA Psychiatry in 2025 examined 247,420 people who had received ADHD medication. It found consistent associations between medicated periods and lower rates of self-harm, unintentional injuries, traffic crashes and crime, although the strength of some associations changed over time [5].
Research from Taiwan has also identified associations between ADHD and increased risks of certain causes of premature mortality, including unintentional injuries [6].
These studies examine different populations and outcomes, and they do not establish identical effects across countries.
Taken together, however, they demonstrate why ADHD should be understood as a significant clinical and public-health concern rather than simply a difficulty with classroom concentration.
5. My Experience: Why Medication Reviews Must Look Beyond the Prescription
Over more than 26 years in pharmacy and healthcare, including approximately a decade of mental-health-related clinical experience, I have learned that effective medicines management requires more than checking a drug name and dose.
Alongside my former responsibilities as a pharmacy owner and Superintendent Pharmacist Director, I undertook locum assignments in England involving NHS hospital and general practice settings.
My work included mental-health medication reviews, medicines optimisation and patient consultations conducted face-to-face, by telephone and, where available, through video appointments.
I also gained experience participating in mental-health assessment processes within appropriate clinical oversight arrangements.
These experiences shaped my understanding of an essential principle:
A medicine should be evaluated not only by what it changes on a clinical measurement scale, but also by what it helps the patient achieve in everyday life.
For example, a person receiving treatment for a mental-health condition may report improved symptoms while continuing to struggle with sleep, adherence, occupational functioning or adverse effects.
A meaningful medication review therefore asks broader questions.
Is the treatment helping the patient function?
Are side effects creating new difficulties?
Are co-existing conditions being recognised?
Is the treatment plan realistic for the person's daily circumstances?
My more recent specialist Adult, Childhood, and Young People with ADHD training through UKAAN and Harley Mental Health, and supervised clinical development in ADHD assessment, diagnostic formulation, medication reviews and titration have reinforced the importance of these questions.
My longstanding mental-health-related experience is distinct from my more recent specialist ADHD training. Both have strengthened my commitment to careful assessment, evidence-based treatment and multidisciplinary clinical care.
6. Medication Matters - But It Is Not the Whole Treatment Plan
The BMJ findings should not be interpreted as suggesting that every person with ADHD requires medication.
Nor should they be used to pressure patients into accepting pharmacological treatment.
NICE guideline NG87 recommends individualised assessment and shared treatment planning that considers symptoms, functional impairment, patient preferences, coexisting conditions and environmental modifications [7].
For adults, medication may be offered when ADHD symptoms continue to cause significant impairment despite appropriate environmental adjustments.
Non-pharmacological interventions may also be appropriate, either independently or alongside medication.
Clinical management requires attention to cardiovascular health, sleep, appetite, weight, adverse effects, treatment response and ongoing review.
Medication initiation and titration must be undertaken by professionals with appropriate ADHD expertise.
This is particularly important because a successful prescription is not simply one that reduces symptoms.
It is one that provides meaningful benefit while maintaining an acceptable balance of safety, tolerability and patient preference.
7. The Responsibility of Healthcare Organisations and Service Leaders
The implications of this research extend beyond individual consultations.
For NHS services, independent healthcare providers and clinical commissioners, the findings raise questions about how ADHD care pathways are designed.
An assessment pathway without timely access to appropriate follow-up and treatment may leave patients with an incomplete service.
Similarly, prescribing without adequate monitoring, clinical governance or continuity of care may compromise the quality of treatment.
Effective ADHD services require coordinated diagnostic assessment, prescribing expertise, appropriate titration, medicines optimisation, safeguarding, documentation and ongoing review.
They also require clear professional responsibilities and effective communication between clinicians and primary-care services.
From my experience in pharmacy leadership, clinical governance and multidisciplinary healthcare environments, I recognise that sustainable services depend on both clinical competence and operational systems.
Healthcare organisations should therefore consider not only how many assessments they can deliver, but also whether patients can access safe, continuous and appropriately monitored care.
The ultimate measure of quality is not simply the number of diagnoses made.
It is whether patients receive care that is safe, evidence-based and capable of improving their lives.
8. Employers Must Also Understand the Wider Picture
Consider an employee who is intelligent, creative and highly motivated but struggles with competing deadlines, distractions or inconsistent organisation.
Without understanding, their difficulties may be mistaken for a poor attitude.
Appropriate ADHD care may improve aspects of functioning, but medication does not replace the need for supportive workplaces.
Practical adjustments can include written instructions, structured priorities, quieter working environments, flexible task organisation and regular feedback.
Employers should avoid assuming that ADHD automatically makes someone unsuitable for demanding professional responsibilities.
Equally, they should not assume that medication alone resolves every difficulty.
The more constructive approach is to evaluate each individual's needs, capabilities and working environment.
Inclusion is not about lowering expectations. It is about ensuring that capable people have a fair opportunity to meet them.
9. Limitations: The Research Questions We Must Still Answer
Despite the strength of the Swedish dataset, several uncertainties remain.
Researchers could not eliminate all possible confounding factors, including differences in illness severity, individual circumstances and treatment adherence.
Prescription records do not necessarily establish whether patients consistently took medication as directed.
The study also did not determine the optimal treatment, dose or duration for preventing each adverse outcome.
Further research should investigate long-term outcomes, individual treatment responses, adverse effects, and the generalisability of findings to more diverse populations.
These questions are particularly important when translating research into UK clinical practice.
A large study can strengthen confidence in an association without proving that the same magnitude of benefit will occur for every patient.
That is why careful clinical judgement remains indispensable.
10. My Closing Reflection:
The Person Behind the Diagnosis
When we talk about ADHD, we often focus on symptoms.
Difficulty concentrating.
Impulsivity.
Disorganisation.
Restlessness.
But patients and families may be asking much more personal questions.
Will I be able to keep my job?
Can I manage my responsibilities?
Will my relationships improve?
Can I feel more confident in everyday life?
Will I be safe?
The Swedish research invites us to take those questions seriously.
It suggests that ADHD treatment may be associated with benefits extending into areas of life that matter profoundly to patients, families and society.
But medication is not a cure, and an ADHD diagnosis does not determine a person's future.
What matters is access to accurate assessment, informed choices, competent clinical care and appropriate support.
We should stop measuring ADHD care solely by whether someone can concentrate for longer.
We should also ask whether their treatment and support are helping them live more safely, independently and meaningfully.
Because behind every clinical statistic is a human life.
And every human life deserves to be understood.
References
[1] Roxby, P. (2025) ‘ADHD drugs have wider life benefits, study suggests’. BBC News, 14 August 2025.
[2] Zhang, L. et al. (2025) ‘ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials’. The BMJ, 390, bmj-2024-083658. https://doi.org/10.1136/bmj-2024-083658
[3] Faraone, S.V. et al. (2021) ‘The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder’. Neuroscience & Biobehavioral Reviews, 128, pp. 789–818. https://doi.org/10.1016/j.neubiorev.2021.01.022
[4] Chang, Z. et al. (2017) ‘Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes’. JAMA Psychiatry, 74(6), pp. 597–603. https://doi.org/10.1001/jamapsychiatry.2017.0659
[5] ‘Increased prescribing of attention-deficit/hyperactivity disorder medication and real-world outcomes over time’ (2025). JAMA Psychiatry. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2835661
[6] ‘Attention-deficit/hyperactivity disorder and mortality risk in Taiwan’ (2019). JAMA Network Open. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2747482
[7] National Institute for Health and Care Excellence (2018, updated subsequently) Attention deficit hyperactivity disorder: diagnosis and management (NG87). https://www.nice.org.uk/guidance/ng87/chapter/recommendations
Clinical disclaimer: This article is an educational, evidence-based commentary. Observational associations do not establish causation, and the findings should not be used to make individual prescribing decisions. ADHD assessment and treatment must be tailored to the patient and undertaken by appropriately qualified professionals.
Dr Emmanuel Eni Amadi, PhD, MBA
ADHD Clinician | Adult, Children & Young People with ADHD | GPhC Registered Pharmacist Independent Prescriber | UKAAN & Harley Mental Heath-Trained | Medical Scientist
Clinical Director, NeuroMetabolic Healthcare Ltd
